Migraine is a debilitating neurological disease, ranking consistently among the top 10 leading causes of years lived with disability, worldwide. The main symptom of migraine is an enduring headache, along with symptoms such as severe pain on one side of the head or throbbing pain, sensitivity to light and sound, and nausea. Despite being a very common headache disorder that affects roughly 15 percent of the adult population worldwide, it remains inadequately understood and most neglected.
In Delhi, approximately 25 per cent of the population suffers from migraines, every year.
While migraine is an invisible condition, it can severely impact individuals across personal, professional and social domains, thus affecting the overall quality of life and productivity. Work-from-home, or the 'new normal,' has drastically impacted the lives of people suffering from migraines from an inability to concentrate at work to missed workdays. It has become even more urgent to ensure that individuals have the understanding and tools to effectively manage migraines.
There is a lack of understanding amongst people about the severity of migraines. In a study we recently conducted, about 50 to 60 per cent of migraineurs were undiagnosed, despite recurrent headaches. Because migraine falls on a spectrum, ranging from infrequent or mild attacks to recurrent ones, many pass it off as merely a headache'. With busy work-from-home schedules, paired with fear of contracting COVID-19 infection and difficulty in accessing in-person care, people are avoiding seeking medical help for the condition, instead attributing symptoms to associated comorbidities, such as stress or depression."
He continued, "Financial worries due to job loss or salary cuts also contribute to aggravated migraine attacks, which is more noticeable recently. The effects of migraine on one's quality of life also reportedly worsened, particularly for many migraineurs working as essential healthcare workers at this time.
Symptom neglect and failure to treat the condition can lead to migraines becoming chronic. A fundamental need is to recognize migraine as a serious condition with severe disability and adopt a holistic treatment approach. Early detection can be a key enabler of a smoother patient journey and an improved quality of life."
Here are 5 ways to manage your migraine while working from home:
Identify Risk Factors and Monitor Triggers
Migraines can begin at any age but tend to peak during one's prime productive years. Moreover, women are three times more likely to be affected than men, with prevalence peaking between the ages of 25 and 55 years.
Long hours of working from home, along with longer screen times, disrupted sleep schedules and irregular eating habits can increase stress levels. For migraineurs, such changes can become migraine triggers, exacerbating their condition. Identifying personal triggers can help individuals manage their migraines better.
Make The Right Choice for Diet and Lifestyle
Working from home can be hard, but a daily routine that optimizes your physical and mental health can help keep your migraine at bay. Eating healthy meals at appropriate times or consuming small, frequent meals throughout the day are associated with less frequent migraine headaches. Taking breaks from work at regular intervals can help you eat right and reduce eye strain owing to excessive screen use. Making modifications to your lifestyle, including smoking cessation and reduced alcohol consumption, and maintaining optimal sleeping habits and exercising regularly can be key to manage migraines. These also benefit migraine prevention and treatment.
Talk to An Expert
It is important to consult a medical specialist when you are experiencing severe headaches that disrupt your daily routine. A lot of migraineurs hesitate to seek medical help. This could be due to several reasons lack of understanding of migraine severity, lack of time due to hectic work-from-home schedules, or recently, due to a reduction in-person clinic consultations owing to the fear of Covid-19 infection. However, consulting a neurologist, even via teleconsultations, is a necessary step to diagnose your condition and understand the available options for acute and chronic management of migraine, including preventive treatment. With evidence-based information on effects across migraine intensity reduction, quality of life and ease of use, neurologists can guide you on the most suitable treatment option to prevent or reduce your migraine episodes.
Track Your Migraines
It is a good idea to maintain a diary (or download a migraine tracker app), to record the time and severity of your migraine attacks, symptoms, daily diet, exercise routines, and medications and side effects. This can help identify triggers and patterns. It can also prompt meaningful conversations with your doctor, contributing to a more holistic treatment plan, personalized to suit your work schedule.
Seek Support From Your Family, Friends or Colleagues
Living with migraines can make one feel helpless, distressed and misunderstood. But talking to your friends and family will help them understand your condition better. Having an open conversation about your migraine with your employer is a good idea, particularly to work out a schedule, with specific routine adjustments to mitigate triggers. This can help you be productive and healthy while working from home. Employers can also take the initiative -- arranging wellness programs for employees to raise awareness about migraines and how to effectively manage them at work and enhance productivity.
Migraine attacks can be challenging. Changes to your daily routine and active communication about your condition with your employer, after consulting a neurologist, can help you better manage migraines as you work from home.
Read More► The Best Ways to Treat A Sun Tan?
London, July 17 (IANS) Although the risk of a child being admitted to hospital due to Covid-19 is small, a new UK study has found that around 1 in 20 children hospitalised with Covid developed brain or nerve complications linked to the viral infection.
The research, published in The Lancet Child and Adolescent Health, identifies a wide spectrum of neurological complications in children and suggests they may be more common than in adults admitted with Covid-19.
"The risk of a child being admitted to hospital due to COVID-19 is small, but among those hospitalised, brain and nerve complications occur in almost 4 per cent," said researcher Stephen Ray from the University of Liverpool.
"Our nationwide study confirms that children with the novel post-infection hyper-inflammatory syndrome PIMS-TS can have brain and nerve problems; but we have also identified a wide spectrum of neurological disorders in children due to Covid-19 who didn't have PIMS-TS," Ray added.
While neurological problems have been reported in children with the newly described post-Covid condition paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS), the capacity of Covid-19 to cause a broad range of nervous system complications in children has been under-recognised.
To address this, the researchers developed a real-time UK-wide notification system in partnership with the British Paediatric Neurology Association.
Between April 2020 and January 2021, they identified 52 cases of children less than 18 years old with neurological complications among 1,334 children hospitalised with Covid-19, giving an estimated prevalence of 3.8 per cent.
This compares to an estimated prevalence of 0.9 per cent in adults admitted with Covid-19.
Eight (15 per cent) children presenting with neurological features did not have Covid-19 symptoms although the virus was detected by PCR, underscoring the importance of screening children with acute neurological disorders for the virus.
For the first time, the study identified key differences between those with PIMS-TS versus those with non-PIMS-TS neurological complications.
The 25 children (48 per cent) diagnosed with PIMS-TS displayed multiple neurological features including encephalopathy, stroke, behavioural change, and hallucinations; they were more likely to require intensive care.
Conversely, the non-PIMS-TS 27 (52 per cent) children had a primary neurological disorder such as prolonged seizures, encephalitis (brain inflammation), Guillain-BarrA¿ syndrome and psychosis.
In almost half of these cases, this was a recognised post-infectious neuro-immune disorder, compared to just one child in the PIMS-TS group, suggesting that different immune mechanisms are at work.
Short-term outcomes were good in two-thirds (65 per cent) although a third (33 per cent) had some degree of disability and one child died at the time of follow-up. However, the impacts on the developing brain and longer-term consequences are not yet known.
Washington, July 13 (IANS) The US Food and Drug Administration (FDA) added a new warning on the Johnson & Johnson Covid-19 vaccine, saying the jabhas been linked to a serious but rare side effect called Guillain-Barre syndrome.Guillain Barre syndrome is a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis, Xinhua news agency reported citing the FDA as saying.The syndrome has occurred in some people who have received the Johnson & Johnson vaccine, the FDA in a letter on Monday. In most of these people, symptoms began within 42 days following injections of the vaccine, it added.The chance of having this occur is very low, the agency said.About 100 preliminary reports of Guillain-Barre syndrome have been detected in vaccine recipients after the administration of 12.8 million doses of the Johnson & Johnson jab in the US, The Washington Post quoted the Centers for Disease Control and Prevention (CDC) as saying in a statement.Of these reports, 95 were serious and required hospitalization, and one had dead.The cases have largely been reported about two weeks after vaccination and mostly in men, many aged 50 and older, according to the CDC.Johnson & Johnson said on Monday it has been in discussions with the FDA and other regulators about rare cases of Guillain-Barre syndrome.The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree, the company said in a statement. --IANSksk/
New Delhi, June 22 (IANS) Eleven individuals who received the AstraZeneca-Oxford Covid-19 vaccine have developed a rare neurological disorder called Guillain-Barre syndrome, clinicians in India and England have reported in two separate studies.The studies, published in the peer-reviewed medical journal Annals of Neurology, describe an unusual variant of Guillain-Barre syndrome characterised by prominent facial weakness. All the eleven cases were among people who had received that vaccine 10-22 days earlier.Seven cases were reported from a regional medical center in Kerala, India, where approximately 1.2 million people were vaccinated with the AstraZeneca Covid-19 vaccine till April 22. The cases occurred within two weeks of the first dose of vaccination."Six out of the seven patients progressed to areflexic quadriplegia and required mechanical ventilatory support," said Boby Varkey Maramattom, from the Department of Neurology, Aster Medcity, Kochi, Kerala."The frequency of GBS was 1.4 to 10 fold higher than that expected in this period for a population of this magnitude. In addition, the frequency of bilateral facial weakness, which typically occurs in less than 20 per cent of GBS cases, suggests a pattern associated with the vaccination," he added.Four cases were reported from Nottingham, England, in which approximately 700,000 people received the same vaccine. These were characterised by bifacial weakness with a paraesthesias variant of GBS occurring within three weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine."This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment," said Jonathan Rhys Evans, Department of Neurology, Nottingham University Hospitals NHS Trust, UK."If the link is causal it could be due to a cross-reactive immune response to the SARS-CoV-2 spike protein and components of the peripheral immune system," wrote the authors of the report from England.While the benefits of vaccination substantially outweigh the risk of this relatively rare outcome (5.8 per million), the research groups stressed that clinicians should be alert to this possible adverse event and look for this rare neurological syndrome following administration of Covid-19 vaccines."We suggest vigilance for cases of bifacial weakness with paraesthesias variant GBS following vaccination for SARS-CoV-2 and that post-vaccination surveillance programmes ensure robust data capture of this outcome, to assess for causality," Evans said.--IANSrvt/dpb
Jodhpur, June 16 (IANS) Controversial self-styled godman Asaram, who is serving a life sentence in connection with a rape case in Jodhpur jail, was shifted to the AIIMS here on Wednesday after he complained of breathing issues owing to post-Covid complications.On May 7, Asaram was admitted to the ICU of MDM Hospital here after testing positive for Covid-19. Later he was shifted to AIIMS Jodhpur.He started complaining of having breathing problem on Tuesday night and by Wednesday morning, his condition worsened following which he was shifted to the hospital. Initially, he had refused to go the hospital, but got admitted after doctor's advice.After preliminary examination, the doctors told him that he is suffering from post-Covid complications.A few tests have been conducted and a preliminary line of treatment is being given to him, confirmed the medical staff at the hospital.When the self-styled godman was admitted to the hospital last month, he had filed a bail petition in the high court expressing his desire to get treated at an Ayurveda hospital.However, his plea was rejected based on his medical report, which was submitted by the AIIMS medical board on the direction of the high court.Asaram then challenged the high court ruling in the Supreme Court. But the state government then stepped in and opposed granting him bail in the top court, saying that apart from AIIMS, Jodhpur has many renowned institutes of Ayurveda besides having quality medical facilities and hence he should not be granted bail.However, the lawyers of Asaram failed to appear in the Supreme Court on Wednesday, forcing the court to adjourn the hearing to June 18.--IANSarc/arm
Jaipur, June 11 (IANS) Renowned neurologist Ashok Panagariya passed away here on Friday after suffering from post-Covid complications.He was in a hospital for over 25 days as his lungs were damaged even as he recovered from Covid.Panagariya has over 90 research papers in different health journals in his name. He has won UNESCO Award for his medical and social cooperation, and was also conferred the Padma Shri. Chief Minister Ashok Gehlot condoled his death."Condolences to renowned neurologist and Padmashri Dr Ashok Panagariya who served significant positions in the medical stream. Even during COVID pandemic, he played a significant role as a medical practitioner in the state," he said in a tweet.--IANSarc/vd